Harvard Bioscience

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Harvard Bioscience reports strong Q4 earnings, eyes China growth

Harvard Bioscience delivered solid financial performance in Q4 2022 with revenue growth and strong margins.
The company faces challenges in supply chain issues and debt reduction but is focused on growth opportunities.
Strategic plans for new product development and improving gross margins are key priorities for future success.

Harvard Bioscience reports strong Q1 earnings, eyes growth opportunities

Harvard Bioscience delivered solid Q1 2023 results with revenue growth, improved margins, and enhanced profitability. While facing challenges in sales organization and market shifts, the company is strategically positioned to capitalize on opportunities for growth through new product offerings and operational efficiencies.

Harvard Bioscience reports mixed Q2 results, eyes growth opportunities

Harvard Bioscience's Q2 2023 performance showed slight revenue decline but notable improvements in margins and profitability.
The company's strengths include new product launches, positive financial metrics, and a promising revenue guidance for 2023.
Challenges include managing discontinued products impact, sales force effectiveness, and profitability.
Opportunities exist in leveraging new products, addressing challenges, and optimizing financial performance drivers.

Harvard Bioscience reports improved margins and profitability in Q3

Harvard Bioscience (HBIO) showed mixed performance in Q3 2023 with revenue decline but improved margins and profitability. The company aims to sustain growth through new product launches and service expansion while managing debt effectively.

Harvard Bioscience reports Q4 results, eyes growth through new products

Harvard Bioscience reported mixed Q4 2023 results with revenue decline in some regions.
The company aims for long-term growth through new products and market expansion.
Challenges include revenue decline in certain regions and maintaining/improving margins.
Opportunities lie in new product launches, partnerships, and market expansion strategies.

Harvard Bioscience faces Q1 revenue dip, eyes second-half turnaround

Harvard Bioscience navigated a tough Q1 marked by revenue declines in key regions and operational challenges. However, the company's focus on new product launches and efficiency in maintaining a strong gross margin are positive indicators. Looking ahead, Harvard Bioscience anticipates a turnaround in the second half of the year with improved margins and overall performance.

Harvard Bioscience reports Q3 revenue decline, eyes growth opportunities

Harvard Bioscience faced revenue decline in Q3 due to China and Asia Pacific weakness but expects stabilization and growth.
Operational improvements and cost reductions are enhancing efficiency and profitability.
New product launches and focus on high-growth areas position the company for incremental growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HOLLISTON, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetings with investors at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21, 2023.

Harvard Bioscience to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21, 2023

Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q4 2022 Earnings Call Transcript March 9, 2023 8:00 AM ET Company Participants Dave Sirois - Director, Corporate Accounting & SEC Reporting Jim Green - Chairman of the Board, President & Chief Executive Officer Jennifer Cote - Interim Chief Financial Officer Conference Call Participants Bruce Jackson - Benchmark Company Harrison Schrage - KeyBanc Operator Good day, and thank you for standing by. Welcome to the Harvard Bioscience Fourth Quarter 2022 Earnings Conference Call.

Harvard Bioscience, Inc. (HBIO) Q4 2022 Earnings Call Transcript

HOLLISTON, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2022.

Harvard Bioscience Announces Fourth Quarter 2022 Financial Results

HOLLISTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2022 before the market opens on March 9, 2023, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Harvard Bioscience Schedules Fourth Quarter 2022 Earnings Conference Call for March 9, 2023 at 8:00 AM ET

Amazon

American Water Works

Costco

eBay

Enservco

Philip Morris

The RealReal

Tesla

Walmart

Welcome to January! The season of holiday gifts

10 Stocks Under $10 for 2023

HOLLISTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Michael Rossi, the Company's chief financial officer and treasurer, effective December 31, 2022. The Company has appointed Jennifer Cote, the Company's vice president of global finance, as its interim chief financial officer and treasurer, effective upon Mr. Rossi's resignation. Mr. Rossi will remain with the Company through May 10, 2023 to provide transition assistance. The Company has initiated a search for a permanent replacement.

Harvard Bioscience Announces CFO Transition

Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants David Sirois - Director, Corporate Accounting & SEC Reporting James Green - President, CEO & Chairman Michael Rossi - CFO Conference Call Participants Paul Knight - KeyBanc Capital Markets Bruce Jackson - The Benchmark Company Operator Good day, and thank you for standing by. Welcome to the Harvard Bioscience Third Quarter 2022 Earnings Call.

Harvard Bioscience, Inc. (HBIO) Q3 2022 Earnings Call Transcript

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -120% and 3.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Harvard Bioscience (HBIO) Reports Q3 Loss, Misses Revenue Estimates

“Fighting through challenging times while building the company and new technologies for the future.”  “Fighting through challenging times while building the company and new technologies for the future.”

Harvard Bioscience Announces Third Quarter 2022 Financial Results

HOLLISTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for third quarter ended September 30, 2022 after the market closes on November 8, 2022, and will hold a conference call to discuss the results at 4:30 p.m. Eastern Time.

Harvard Bioscience Schedules Third Quarter 2022 Earnings Conference Call for November 8, 2022 at 4:30 PM ET

Harvard Bioscience is a small-cap life-science technology company that is trading at a significant discount after falling ~67% over the past twelve months despite the ticker's significant upside potential. I believe the market-wide sell-off has provided me with an opportunity to grow HBIO into a larger element of my Compounding Healthcare “Bio Boom” Portfolio.

Harvard Bioscience: Undervalued, Underfollowed, And A Perfect Candidate For My 'Bio Boom' Portfolio

Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants David Sirois - Director of Corporate Accounting & SEC Reporting Jim Green - President & Chief Executive Officer Mike Rossi - Chief Financial Officer Conference Call Participants Bruce Jackson - The Benchmark Company Paul Knight - KeyBanc Capital Markets Operator Good day, and thank you for standing by. Welcome to the Q2 2022 Harvard Bioscience, Inc. Earnings Conference Call.

Harvard Bioscience, Inc. (HBIO) CEO Jim Green on Q2 2022 Results - Earnings Call Transcript

HOLLISTON, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter ended June 30, 2022.

Harvard Bioscience Announces Second Quarter 2022 Financial Results

HOLLISTON, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2022 before the market opens on August 4, 2022, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Harvard Bioscience Schedules Second Quarter 2022 Earnings Conference Call for August 4, 2022 at 8:00 AM ET

Harvard Bioscience (HBIO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Harvard Bioscience (HBIO) Loses 35.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q1 2022 Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants David Sirois - Director of Corporate Accounting & SEC Reporting James Green - President & Chief Executive Officer Michael Rossi - Chief Financial Officer Conference Call Participants Paul Knight - KeyBanc Capital Markets Tim Chiang - Northland Capital Markets Bruce Jackson - The Benchmark Company Operator Good morning, ladies and gentlemen. Thank you for standing by and welcome to the Harvard Bioscience, Inc. First Quarter 2022 Earnings Conference Call.

Harvard Bioscience, Inc. (HBIO) CEO James Green on Q1 2022 Results - Earnings Call Transcript

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -20% and 1.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Harvard Bioscience (HBIO) Q1 Earnings and Revenues Lag Estimates

HOLLISTON, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2022.

Harvard Bioscience Announces First Quarter 2022 Financial Results

Company continues innovating preclinical tools used in new and ongoing small animal research and product development with SmartStudy™ Company continues innovating preclinical tools used in new and ongoing small animal research and product development with SmartStudy™

Harvard Bioscience Introduces SmartStudy™: First of Kind, Next Generation Inhalation System Capability Improves Precision and Drives Growth

HOLLISTON, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for first quarter ended March 31, 2022 before the market opens on May 4, 2022, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Harvard Bioscience Schedules First Quarter 2022 Earnings Conference Call for May 4, 2022 at 8:00 AM ET

Harvard Bioscience (HBIO) is a small-cap, life-science technology company that is underfollowed.

Harvard Bioscience - Dressed Up And Waiting For A Suitor

Harvard Bioscience, Inc. (HBIO) CEO James Green on Q4 2021 Results - Earnings Call Transcript

HOLLISTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the period ended December 31, 2021.

Harvard Bioscience Announces Fourth Quarter 2021 Financial Results

HOLLISTON, Mass., Feb. 21, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2021 before the market opens on March 8, 2022, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Harvard Bioscience Schedules Fourth Quarter 2021 Earnings Conference Call for March 8, 2022 at 8:00 AM ET

Harvard Bioscience, Inc. (HBIO) CEO James Green on Q3 2021 Results - Earnings Call Transcript

News for Harvard Bioscience Stock (HBIO)